Q-omics provides the consensus-scored FOXA1 profile across patient tissues and cancer cell-line models. FOXA1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FOXA1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, FOXA1 RNA expression shows 17,533 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, HNSC, and BRCA as cancer lineages where FOXA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXA1 survival associations across molecular data types. FOXA1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXA1 RNA expression–survival associations across cancer types. High FOXA1 expression shows unfavorable associations in KIRC, KIRP, MESO and THCA, but favorable associations in BLCA and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FOXA1 RNA expression.
This table summarizes FOXA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FOXA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXA1 shows lower tumor expression in HNSC and COAD and higher tumor expression in LUAD, BRCA, UCEC and THCA. The HNSC box plot shows higher FOXA1 RNA expression in normal versus tumor tissue (log2 FC = −3.295, t-test p < 0.001).
This table shows molecular features associated with FOXA1 in patient tissues and cancer cell lines. In patient samples, FOXA1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
